Explore
Trendline
CareDx Reports Strong Q1 2026 Financial Results with 39% Revenue Growth
CareDx Reports Strong Q1 2026 Financial Results with 39% Revenue Growth
Read More
Trendline
Encompass Health Reports Strong Q1 2026 Results with Revenue and EBITDA Growth
Encompass Health Reports Strong Q1 2026 Results with Revenue and EBITDA Growth
Read More
Trendline
Amylyx Pharmaceuticals to Announce Q1 2026 Financial Results Amid Strategic Focus on Neurodegenerative Diseases
Amylyx Pharmaceuticals to Announce Q1 2026 Financial Results Amid Strategic Focus on Neurodegenerative Diseases
Read More
Trendline
Stellantis Reports Q1 2026 Financial Results with 6% Revenue Increase
Stellantis Reports Q1 2026 Financial Results with 6% Revenue Increase
Read More
Trendline
ADAMA Ltd. Reports 4% Revenue Growth in Q1 2026 Amid Portfolio Optimization
ADAMA Ltd. Reports 4% Revenue Growth in Q1 2026 Amid Portfolio Optimization
Read More
Trendline
Alignment Healthcare Reports Profit Amid Medicare Advantage Membership Growth
Alignment Healthcare Reports Profit Amid Medicare Advantage Membership Growth
Read More
Trendline
Lucid Diagnostics Announces Upcoming Business Update Conference Call
Lucid Diagnostics Announces Upcoming Business Update Conference Call
Read More
Trendline
Co-Diagnostics to Release Q1 2026 Financial Results, Hosts Webcast for Analysts
Co-Diagnostics to Release Q1 2026 Financial Results, Hosts Webcast for Analysts
Read More
Trendline
Merck Reports Q1 CY2026 Earnings, Exceeds Analyst Expectations
Merck Reports Q1 CY2026 Earnings, Exceeds Analyst Expectations
Read More
Trendline
CareDx Reports 39% Revenue Growth in Q1 2026, Raises Annual Guidance
CareDx Reports 39% Revenue Growth in Q1 2026, Raises Annual Guidance
Read More
Trendline
NeoGenomics Announces 11% Revenue Growth in Q1 2026, Raises Full-Year Guidance
NeoGenomics Announces 11% Revenue Growth in Q1 2026, Raises Full-Year Guidance
Read More
Trendline
AstraZeneca Reports Strong Q1 2026 Revenue Growth Driven by Oncology and Rare Disease
AstraZeneca Reports Strong Q1 2026 Revenue Growth Driven by Oncology and Rare Disease
Read More
